ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration /



TOKYO, Oct 21, 2025 - (JCN Newswire) - Olympus Corporation (Olympus), today announced that the feasibility study project entitled “Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India,” jointly proposed with Saraya Co., Ltd. (hereinafter “SARAYA”), has been selected by the Ministry of Economy, Trade and Industry (METI) under its FY2024 supplementary “Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration/Feasibility Study Project)” on August 1, 2025.

The selected feasibility study project (hereinafter the “Project”), supported by METI, will evaluate the feasibility of introducing Japan’s established infection control systems to India, aiming to enhance the safety and reliability of the endoscopic medical environment.

In India, endoscopic procedures already outnumber those in Japan and are expected to grow further due to the country’s large and expanding population. However, compared to Japan, infection control systems are still evolving in terms of both technology and operational processes. For instance, many medical institutions still rely on manual cleaning methods although awareness and adoption of automated endoscope reprocessors are gradually increasing. In contrast, Japan has established rigorous academic guidelines and widely adopted digital endoscope reprocessing systems that minimize human error and ensure high standards of infection control.

The Project, in collaboration with the Department of Infection Control and Prevention and the Department of Gastroenterology at the University of Tokyo Hospital, will investigate the feasibility of transferring Japan’s endoscopic infection control system to India. Medical experts from Indian medical institutions will be invited to Japan, where training and site visits at the University of Tokyo Hospital will help deepen their understanding of the Japanese infection control system. In parallel, experts from the University of Tokyo Hospital will visit medical institutions in India to assess the environment of endoscopy and reprocessing units, identify key challenges, and engage in discussions with Indian experts toward building a safer and more reliable endoscopic medical environment.

Olympus has identified six focus areas, including “Healthcare Access and Outcome” and “Compliance, Product Quality and Safety.” Initiatives that deliver training and skill development opportunities for healthcare professionals, and ensure the quality and safety of products, services, and solutions are a top priority. Olympus remains committed to protecting the safety of patients and healthcare professionals, while leveraging Japanese technology to advance global medical standards.

About Saraya Co., Ltd.

SARAYA is committed to creating a prosperous and sustainable global society under the three core pillars of “Hygiene,” “Environment,” and “Health.” Since its founding in 1952, SARAYA has developed and delivered a wide range of products and services, from detergents and disinfectants to health foods, serving both professional and household markets.  https://saraya.world/

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global LinkedIn and X accounts.

Media contact:
Mail: Global-Public_Relations@olympus.com 

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com  

]]>

Source: Olympus

Copyright 2025 JCN Newswire . All rights reserved.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.20
+0.88 (0.35%)
AAPL  270.14
+0.10 (0.04%)
AMD  256.33
+6.28 (2.51%)
BAC  52.45
-1.09 (-2.04%)
GOOG  284.75
+6.69 (2.41%)
META  635.95
+8.63 (1.38%)
MSFT  507.16
-7.17 (-1.39%)
NVDA  195.21
-3.48 (-1.75%)
ORCL  250.31
+2.14 (0.86%)
TSLA  462.07
+17.81 (4.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.